Swiss stocks - Factors to watch on November 9
Swiss stocks - Factors to watch on November 9 ZURICH/GDANSK, Nov 9 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Monday:
UBS Group AG UBSG.S
UBS Chief Executive Sergio Ermotti said on Monday a sharp correction in AI stocks over the last few weeks had been a reaction to excessively high hopes that investors had had for the sector.
ABB LTD ABBN.S
Japan's SoftBank and Swiss engineering group ABB are looking at carving out the Chinese element of a $5.4 billion robotics deal which was blocked earlier this week by Beijing, Bloomberg News reported on Saturday, citing people familiar with the matter.
NOVARTIS AG NOVN.S
The US Food and Drug Administration said on Friday it was investigating a risk of neoplasia, or tumour formation including malignancy, associated with Novartis' gene therapy Zolgensma.
ECONOMY
SNB sight deposits due at 0900 GMT.
(Reporting by Zurich newsroom and Gdansk newsroom)
((+41 58 306 7336; zurich.newsroom@thomsonreuters.com))
For Top News in a multimedia Web format on Eikon visit: https://bit.ly/2NDFd6g
FOR RELATED PRICES, NEWS AND OTHER TOPICS, DOUBLE-CLICK ON:
Daily Swiss stock market report in German .SDE
All SMI constituent stocks 0#.SSMI
DJ STOXX index .STOXX
Top 10 STOXX sectors .PGL.STOXXS
Top 10 EUROSTOXX sectors .PGL.STOXXES
Swiss mid-cap index .SSMI
Swiss all-share index .SSHI
Swiss market digest .AD.S
Sector overview CH/SECTOR1
All Swiss news CH
Swiss research news CH-RCH
All equity news E
SPEED GUIDES: EQUITY, EQUITY/NEWS1, EUR/EQUITY, SWITZERLAND, REUTERS
Recent news on Novartis AG
See all newsUS FDA approves Bayer's blood thinner to prevent repeat strokes
Brief: Novartis Capital Files For Four-Part Notes Offering, Size Not Disclosed - SEC Filing
Swiss stocks - Factors to watch on November 9
Trial failures of Novartis, Novo Nordisk heart drugs leave experts guessing
FDA probes tumour risk tied to Novartis gene therapy (updated)